Metabolic syndrome is common in psoriatic arthritis and is a known risk factor for worse symptoms and poor treatment outcomes. This study sought to explore the syndrome's role in a more precisely ...

APEX shows Tremfya is the first IL-23 inhibitor to slow joint damage in psoriatic arthritis, offering early, multi-domain ...

About one-third of psoriasis sufferers develop psoriatic arthritis, with swelling, tenderness and pain in joints, affecting daily activities and lifestyle. Psoriatic arthritis (PsA) is a chronic ...

Dr. Michael Garshick discusses recently published recommendations for cardiovascular risk screening for patients with ...

Arthritis awareness emphasizes early detection of arthritis, a condition affecting joints, bones, and muscles. Recognizing ...

European researchers unveil digital tools and explainable AI that personalize psoriatic arthritis care, enabling early ...

New data from the POETYK PsA-Phase III trial, presented at the 2025 EULAR Congress, demonstrate that Bristol Myers Squibb’s Sotyktu (deucravacitinib) significantly improves joint and skin symptoms in ...

Sudden joint pain, or arthralgia, can stem from various causes, ranging from viral infections like the flu and COVID-19 to ...